NCRI 2016 | Faster, smarter, less expensive: opinion on drug development costs

Robert Coleman, MBBS, MD, FRCP, FRCPE of Sheffield Cancer Research, University of Sheffield, UK discusses costs of drug development. With new drugs licensed at a price of $100,000/year, which is not sustainable for common conditions. Many failures in drug development need to be paid for by successful products. Dr Coleman mentions that the process of drug development is complex, bureaucratic, and requires a lot of data, which makes it very expensive. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.